Skip to main content
Equibles
ELTX logo

ELTX · Elicio Therapeutics, Inc.

Track ELTX — free

Use ELTX with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about ELTX

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$3.08 -0.06 (-1.76%) At close · Aug 20
Going-concern doubt — flagged Aug 13, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Our losses from operations, negative operating cash flows and accumulated deficit, as well as the additional capital needed to fund operations for at least twelve months following the issuance of the condensed consolidated financial statements, raise substantial doubt about our ability to continue as a going concern.”
View the 10-Q filed Aug 13, 2026
Market Cap
$80.95M
Shares
26.28M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$3.08 Open$3.11 Day$3.02–3.14 52W close$2.76–14.85 Avg vol 30d351K Short int1.7M · 6.7% float · 5.1d Short vol77% Last earningsJun 15, 2026 DataJun 2023–Aug 2026 Filing10-Q · Aug 13

Raw chart and full-history price indicators begin at the captured split on Jun 2, 2023; bars on opposite sides are not compared.

Up next

FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 13, 2026

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Very Weak Sentiment Bullish Fundamentals Fair Quant / Vol Very High
Market backdrop VIX 14.9 · calm Equity put/call 0.52
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −63%
below
Price vs 50-day avg −23%
below
RSI (14) 41
neutral
MACD trend Positive
52-week position 3%
near low
Momentum
relative strength
Very Weak
1-month return −2%
trailing
6-month return −76%
trailing
YTD return −61%
this year
Relative strength −88%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $4 › 200d $8 — 200d above 50d
Institutional flow Accumulating
+12% holders QoQ · +28 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
6.65% of float · ▼ -6.8% MoM · 5.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
55 holders — near 3-yr high, broad support
Squeeze score 58
elevated · 0–100
Fundamentals
Fair
Revenue growth −92%
Y/Y
EPS growth +39%
Y/Y
Free cash flow $-37.0M
Balance sheet $9.2M
net cash
Quant / Vol
risk profile
Very High
Volatility 142%
annualized · 1-yr
Max drawdown −81%
past year
ATR 9.4%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
3 · 2 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−63% Bearish
Price vs 50-day avg
−23% Bearish
RSI (14)
41 Neutral
MACD trend
Positive Bullish
52-week position
3% Bearish
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $4 › 200d $8 — 200d above 50d
Institutional flow Accumulating
+12% holders QoQ · +28 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
6.65% of float · ▼ -6.8% MoM · 5.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
55 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $3 Now $3 · 3% Range high $15
vs 200-day avg -63% vs 50-day avg -23%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
ELTX
Elicio Therapeutics, Inc.
this stock
$80.95M -61.4% -91.9% — 6.7%
ONC
BeOne Medicines Ltd.
 $557.05B +21.5% +22179.2% 856.5 0.1%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $136.93B +19.2% +46.2% 31.5 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
 $86.39B +7.1% +20.8% 20.8 3.3%
MRNA
Moderna, Inc.
 $69.62B +352.1% +4.3% — 12.5%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
55
% held
22.1%
Net QoQ
+2.7M sh
Top holder
Knoll Capital Management,…
Held Float
View
Held by Funds
Fund positions
16
View
Short & Settlement
Short Interest Falling
Shares short
1.7M
Days to cover
5.1d
Change
-127.9K sh
View
Short Volume
Short vol %
77%
As of
Aug 20, 2026
Short Total
View
Fails to Deliver
FTD shares
6.9K
Value
$20.0K
As of
Jul 31, 2026
View
Off-Exchange
Off-exchange %
45.4%
Week of
Jul 13, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$2.3M
Net income (FY)
$-39.6M
EPS diluted
$-2.58
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 13, 2026
This year
13
View
Exempt Offerings
Offering
$6.0M
Filed
Mar 29, 2024
View
Earnings & Events
Earnings Calls
Last call
Jun 15, 2026
View

Performance

Raw-price comparisons begin at the captured split on Jun 2, 2023; windows that need an earlier baseline remain unavailable.

5D 20D 120D MTD YTD
ELTX -2.4% -2.4% -76.3% +9.8% -61.4%
SPY -2.0% +3.3% +11.2% +2.1% +11.8%
vs SPY -0.4% -5.7% -87.5% +7.7% -73.2%
Key facts CIK 1601485 CUSIP 28657F103 13F (30d) 51 filings 51 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)